The Patent Finder

Invivogen

7 patents currently held · Updated Nov 20, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Pro-Cyclic Dinucleotides and Pro-Cyclic Dinucleotide Conjugates for Cytokine Induction (US 11,730,817) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Sep 29, 2027
    The maintenance fee for Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists (US 9,295,732) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,435,777CPG-free gene for a new secreted reporter protein
In force
 · USPTO record
In forceUSPTO record
US 9,295,732Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
In force
 · USPTO record
In forceUSPTO record
US 9,458,184Compositions of TLR7 and/or TLR8 agonists conjugated to lipids
In force
 · USPTO record
In forceUSPTO record
US 9,567,336Conjugated TLR7 and/or TLR8 and TLR2 agonists
In force
 · USPTO record
In forceUSPTO record
US 10,705,076Anti-HLA monoclonal chimeric immunoglobulin, method and kit implementing such a monoclonal chimeric immunoglobulin
In force
 · USPTO record
In forceUSPTO record
US 9,637,538Anti-HLA monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin
In force
 · USPTO record
In forceUSPTO record
US 11,730,817Pro-Cyclic Dinucleotides and Pro-Cyclic Dinucleotide Conjugates for Cytokine Induction
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 7: 4 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 no status recorded

Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/226,515Pro-Cyclic Dinucleotides and Pro-Cyclic Dinucleotide Conjugates for Cytokine InductionJul 26, 2023Pending
16/176,472Oct 31, 2018No status recorded
15/535,864Dec 9, 2015No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited